146 related articles for article (PubMed ID: 20973932)
1. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.
Lee JT; Li L; Brafford PA; van den Eijnden M; Halloran MB; Sproesser K; Haass NK; Smalley KS; Tsai J; Bollag G; Herlyn M
Pigment Cell Melanoma Res; 2010 Dec; 23(6):820-7. PubMed ID: 20973932
[TBL] [Abstract][Full Text] [Related]
2. Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity.
Pich C; Teiti I; Sarrabayrouse G; Gallardo F; Gence R; Tilkin-Mariamé AF
PLoS One; 2016; 11(2):e0148095. PubMed ID: 26828592
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal.
Lu Y; Zhao Y; Liu P; Xu X
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37643458
[TBL] [Abstract][Full Text] [Related]
4. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.
Ohanna M; Cerezo M; Nottet N; Bille K; Didier R; Beranger G; Mograbi B; Rocchi S; Yvan-Charvet L; Ballotti R; Bertolotto C
Genes Dev; 2018 Mar; 32(5-6):448-461. PubMed ID: 29567766
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity.
Bianchi-Smiraglia A; Wawrzyniak JA; Bagati A; Marvin EK; Ackroyd J; Moparthy S; Bshara W; Fink EE; Foley CE; Morozevich GE; Berman AE; Shewach DS; Nikiforov MA
Cell Death Differ; 2015 Nov; 22(11):1858-64. PubMed ID: 25909885
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Patrawala S; Puzanov I
Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
[TBL] [Abstract][Full Text] [Related]
7. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB; Hauschild A; Robert C; Haanen JB; Ascierto P; Larkin J; Dummer R; Garbe C; Testori A; Maio M; Hogg D; Lorigan P; Lebbe C; Jouary T; Schadendorf D; Ribas A; O'Day SJ; Sosman JA; Kirkwood JM; Eggermont AM; Dreno B; Nolop K; Li J; Nelson B; Hou J; Lee RJ; Flaherty KT; McArthur GA;
N Engl J Med; 2011 Jun; 364(26):2507-16. PubMed ID: 21639808
[TBL] [Abstract][Full Text] [Related]
8. Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.
Choi J; Landrette SF; Wang T; Evans P; Bacchiocchi A; Bjornson R; Cheng E; Stiegler AL; Gathiaka S; Acevedo O; Boggon TJ; Krauthammer M; Halaban R; Xu T
Pigment Cell Melanoma Res; 2014 Mar; 27(2):253-62. PubMed ID: 24283590
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
10. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
11. The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells.
Chen Y; Sang Y; Li S; Xue J; Chen M; Hong S; Lv W; Sehgal K; Xiao H; Liu R
Transl Oncol; 2024 Jul; 45():101991. PubMed ID: 38728872
[TBL] [Abstract][Full Text] [Related]
12. BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience.
Trinder SM; McKay C; Power P; Topp M; Chan B; Valvi S; McCowage G; Govender D; Kirby M; Ziegler DS; Manoharan N; Hassall T; Kellie S; Heath J; Alvaro F; Wood P; Laughton S; Tsui K; Dodgshun A; Eisenstat DD; Endersby R; Luen SJ; Koh ES; Sim HW; Kong B; Gottardo NG; Whittle JR; Khuong-Quang DA; Hansford JR
Front Oncol; 2023; 13():1154246. PubMed ID: 37124503
[TBL] [Abstract][Full Text] [Related]
13. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials.
Song Y; Bi Z; Liu Y; Qin F; Wei Y; Wei X
Genes Dis; 2023 Jan; 10(1):76-88. PubMed ID: 37013062
[TBL] [Abstract][Full Text] [Related]
14. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
Nelson BE; Roszik J; Janku F; Hong DS; Kato S; Naing A; Piha-Paul S; Fu S; Tsimberidou A; Cabanillas M; Busaidy NL; Javle M; Byers LA; Heymach JV; Meric-Bernstam F; Subbiah V
NPJ Precis Oncol; 2023 Feb; 7(1):19. PubMed ID: 36801912
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.
Li Q; Li Z; Luo T; Shi H
Mol Biomed; 2022 Dec; 3(1):47. PubMed ID: 36539659
[TBL] [Abstract][Full Text] [Related]
16. Leveraging Tissue Engineering for Skin Cancer Models.
Oudda S; Ali AM; Chien AL; Park S
Adv Exp Med Biol; 2023; 1410():97-113. PubMed ID: 36484897
[TBL] [Abstract][Full Text] [Related]
17. From simplicity to complexity in current melanoma models.
Michielon E; de Gruijl TD; Gibbs S
Exp Dermatol; 2022 Dec; 31(12):1818-1836. PubMed ID: 36103206
[TBL] [Abstract][Full Text] [Related]
18. Updated Functional Roles of NAMPT in Carcinogenesis and Therapeutic Niches.
Lin TC
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565188
[TBL] [Abstract][Full Text] [Related]
19. Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs.
Gangoda L; Schenk RL; Tai L; Szeto P; Cheung JG; Strasser A; Lessene G; Shackleton M; Herold MJ
Cell Death Dis; 2022 Apr; 13(4):301. PubMed ID: 35379799
[No Abstract] [Full Text] [Related]
20. Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling.
Whiteaker JR; Sharma K; Hoffman MA; Kuhn E; Zhao L; Cocco AR; Schoenherr RM; Kennedy JJ; Voytovich U; Lin C; Fang B; Bowers K; Whiteley G; Colantonio S; Bocik W; Roberts R; Hiltke T; Boja E; Rodriguez H; McCormick F; Holderfield M; Carr SA; Koomen JM; Paulovich AG
Cell Rep Methods; 2021 Jul; 1(3):. PubMed ID: 34671754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
